alexa Clinical Prognostic Models in Diffuse Large B Cell Lymphoma Patients are Still Essential in the Rituximab Era
ISSN: 2329-8790

Journal of Hematology & Thromboembolic Diseases
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Clinical Prognostic Models in Diffuse Large B Cell Lymphoma Patients are Still Essential in the Rituximab Era

Renata de Oliveira Costa1,2*, Abrahão Hallack Neto3, Sheila Siqueira1, Luis Alberto de Padua Covas Lage1, Henrique Moura de Paula4 and Juliana Pereira1

1Universidade de São Paulo, Brazil

2Centro Universitário Lusíada (UNILUS), Universidade de São Paulo, Brazil

3Universidade Federal de Juiz de Fora, Brazil

4Universidade Federal de Goiás, Brazil

*Corresponding Author:
Renata de Oliveira Costa
Avenida Doutor Bernardino de Campos 632 Apartamento 81
CEP, Santos-SP, 11065-002, Brazil
Tel: 5513997829789
Fax: 553240095142
E-mail: [email protected]

Received date: May 16, 2016; Accepted date: July 11, 2016; Published date: July 18, 2016

Citation: Costa RO, Neto AH, Siqueira S, Lage LAPC, Paula HM, et al. (2016) Clinical Prognostic Models in Diffuse Large B Cell Lymphoma Patients are Still Essential in the Rituximab Era. J Hematol Thrombo Dis 4:248. doi:10.4172/2329-8790.1000248

Copyright: © 2016, Costa RO, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Introduction: To evaluate a new enhanced IPI proposal by the National Comprehensive Cancer Network (NCCNIPI) in DLBCL patients, we compared the IPI, R-IPI, and NCCN-IPI in DLBCL patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP).

Methods: From June 2008 to January 2012, we retrospectively evaluated 146 DLBCL patients treated with RCHOP- 21 referred for cancer treatment in a single institution in Brazil. Patients' clinical data were assessed to calculate the IPI, R-IPI, and NCCN-IPI.

Results: Patients' median age was 58.9 years (range 16-86); 85 (57.8%) were female. According to IPI, risk categories were low (n=41, 28.1%), low-intermediate (n=43, 29.5%), high-intermediate (n=37, 25.3%), and high (n=25, 17.1%). Using R-IPI, risk categories were very good (n=19, 13%), good (n=65, 44.5%), and poor (n=62, 42.5%). According to NCCN-IPI, risk categories were low (n=12/147, 8.2%), low-intermediate (n=52/147, 35.6%), high-intermediate (n=62/147, 42.5%), and high (n=20/147, 13.7%). The median follow up was 42.8 months (0.6-71.2) with an overall survival (OS) at 48 months of 73.8% and 84.3% of PFS. Using IPI, the OS at was higher for low and low- intermediate risk than high and high-intermediate risk patients (85.9% vs. 59.2% p<0.001). The RIPI showed significant differences in OS (100% vs. 83.2% vs. 57.5% p<0.001) but not for PFS (p=0.67) among very good, good and poor risk groups. The NCCN-IPI demonstrated significant differences in OS (p<0.001) among lowintermediate, high-intermediate, and high-risk groups, with the high-risk group exhibiting worse OS (35% at 48 months) but not for PFS (0.166). According to IPI, the OS in high-intermediate and high-risk patients was 59.2%. Conclusion: In our study, the NCCN-IPI (but not the IPI or R-IPI) was able to discriminate a group of patients of higher risk of DLBCL treated with R-CHOP with worse median OS.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords